Research Institute for the Care of Older People, Royal United Hospital, Bath BA1 3NG, UK.
Alzheimers Res Ther. 2010 Sep 13;2(5):25. doi: 10.1186/alzrt49.
Dimebon (latrepirdine) has received widespread publicity as a potential therapy for Alzheimer's disease following a very positive phase 2 study carried out in Russia and published in the Lancet in 2008. In this study there were improvements over 6 months in all endpoints (cognitive, global, daily function and behaviour), with continuing improvement at 12 months in cognition and daily function. A more recent multinational phase 3 study, however, showed no improvements whatsoever and no difference between the two drug-treated groups and the placebo group. Of note, there was little deterioration in any of the groups after 6 months in contrast to the placebo group in the phase 2 study. The potential reasons for these disappointing results are discussed, as well as the implication for dimebon and drug treatment in Alzheimer's disease.
地美溴铵（拉替拉滨）在俄罗斯进行的一项非常积极的 2 期研究发表在《柳叶刀》杂志上后，作为阿尔茨海默病的潜在治疗方法引起了广泛关注。在这项研究中，所有终点（认知、整体、日常功能和行为）在 6 个月内都有改善，认知和日常功能在 12 个月时仍在继续改善。然而，最近一项多中心 3 期研究显示，两种药物治疗组与安慰剂组之间没有任何改善，也没有差异。值得注意的是，与 2 期研究中的安慰剂组相比，任何一组在 6 个月后都没有明显恶化。讨论了这些令人失望的结果的潜在原因，以及对地美溴铵和阿尔茨海默病药物治疗的影响。
